Treatment of polymorphic light eruption

Photodermatology Photoimmunology and Photomedicine

Volumn 19, Issue 5, 2003, Pages 217-227

  Ling, Tsui C ^a   Gibbs, Neil K ^a   Rhodes, Lesley E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Polymorphic light eruption; Review; Treatment

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTIOXIDANT; ASCORBIC ACID; AZATHIOPRINE; BETA CAROTENE; BETAMETHASONE DIPROPIONATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; FERULIC ACID; FISH OIL; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; METHOXSALEN; METHOXSALEN DERIVATIVE; NICOTINAMIDE; OMEGA 3 FATTY ACID; PREDNISOLONE; PSORALEN; SUNSCREEN; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DESENSITIZATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG EFFICACY; EXFOLIATIVE DERMATITIS; EYE TOXICITY; FATIGUE; HUMAN; IMMUNOPATHOGENESIS; MOOD DISORDER; PAPULE; PERIPHERAL NEUROPATHY; PHOTOCHEMOTHERAPY; PHOTODERMATOSIS; PHOTOSENSITIVITY; PHOTOTHERAPY; PRIORITY JOURNAL; PROTECTIVE CLOTHING; PUVA; RADIATION DOSE; RECURRENT DISEASE; RETINOPATHY; REVIEW; SUN EXPOSURE; VASCULITIS;

ADRENAL CORTEX HORMONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOCHEMOTHERAPY; PHOTOSENSITIVITY DISORDERS; PHOTOTHERAPY; PRIMARY PREVENTION; SUNLIGHT; SUNSCREENING AGENTS;

EID: 0141849025     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0781.2003.00048.x     Document Type: Review

References (87)

1. Bateman D. Delineations of cutaneous disease. London: Longman, 1817.
2. Rasch C. Om et polymorft (erythematost, vesikulost og ekzematoidt) lysudslet. Hospitalstid 1900; 43: 478-480.
3. Pao C, Norris PG, Corbett M, Hawk JLM. Polymorphic light eruption: prevalence in Australia and England. Br J Dermatol 1994; 130: 62-64.
4. Morison WL, Stern RS. Polymorphous light eruption: a common reaction uncommonly recognized. Acta Dermatol Venereol 1982; 62: 237-240.
5. Ros AM, Wennersten G. Current aspects of polymorphous light eruptions in Sweden. Photodermatology 1986; 3: 298-302.
6. Berg M, Ros AM, Berne B. Ultraviolet A phototherapy and trimethylpsoralen UVA photochemotherapy in polymorphous light eruption - a controlled study. Photodermatol Photoimmunol Photomed 1994; 10: 139-143.
7. Guarrera M, Micalizzi C, Rebora A. Heterogeneity of polymorphous light eruption: a study of 105 patients. Arch Dermatol 1993; 129: 1060-1061.
8. Jansen CT. The natural history of polymorphous light eruptions. Arch Dermatol 1979; 115: 165-169.
9. Petzelbauer P, Binder M, Nikolakis P, et al. Severe sun sensitivity and the presence of antinuclear antibodies in patients with polymorphous light eruption-like lesions: a forme fruste of photosensitive lupus erythematosus? J Am Acad Dermatol 1992; 26: 68-74.
10. Stratigos AJ, Antoniou C, Katsambas AD. Polymorphous light eruption. J Eur Acad Dermatol Venereol 2002; 16: 193-206.
11. Norris PG, Morris J, McGibbon DM, Chu AC, Hawk JLM. Polymorphic light eruption: an immunopathological study of evolving lesion. Br J Dermatol 1989; 120: 173-183.
12. Kolgen W, Van Weelden H, Den Hengst S, et al. CD11b+ cells and ultraviolet-B-resistant CD1a+ cells in skin of patients with polymorphous light eruption. J Invest Dermatol 1999; 113: 4-10.
13. Millard TP, Bataille V, Snieder H, Spector TD, McGregor JM. The heritability of polymorphic light eruption. J Invest Dermatol 2000; 115: 467-470.
14. McGregor JM, Grabczynska S, Vaughan R, Hawk JL, Lewis CM. Genetic modeling of abnormal photosensitivity in families with polymorphic light eruption and actinic prurigo. J Invest Dermatol 2000; 115: 471-476.
15. Leroy D, Dompmartin A, Faguer K, Michel M, Verneuil L. Polychromatic phototest as a prognostic tool for polymorphic light eruption. Photodermatol Photoimmunol Photomed 2000; 16: 161-166.
16. Mastalier U, Kerl H, Wolf P. Clinical, laboratory, phototest and phototherapy findings in polymorphic light eruptions: a retrospective study of 133 patients. Eur J Dermatol 1998; 8: 554-559.
17. Salomon N, Messer G, Dick D, Plewig G, Rocken M. Phototesting for polymorphic light eruption (PLE) with consecutive UVA1/UVB-irradiation. Photodermatol Photoimmunol Photomed 1997; 13: 72-74.
18. Ling TC, Rhodes LE. The clinical findings and phototest results in polymorphic light eruption. AAD poster abstract, San Francisco, March 2003.
19. British Photodermatology Group. Photopatch testing - methods and indications. Br J Dermatol 1997; 136: 371-376.
20. Robson J, Diffey BL. Textiles and sun protection. Photodermatol Photoimmunol Photomed 1990; 7: 32-34.
21. Gies HP, Roy CR, Elliott G, Zongli W. Ultraviolet radiation protection factors for clothing. Health Phys 1994; 67: 131-139.
22. Farr PM, Diffey BL. Adverse effects of sunscreens in photosensitive patients. Lancet 1989; 1: 429-431.
23. Stege H, Budde M, Grether-Beck S, et al. Sunscreens with high SPF values are not equivalent in protection from UVA induced polymorphous light eruption. Eur J Dermatol 2002; 12: IV-VI.
24. Proby C, Baker C, Morton O, Hawk JLM. New broad-spectrum sunscreen for Polymorphic Light Eruption. Lancet 1993; 341: 1347-1348.
25. Allas S, Lui H, Moyal D, Bissonnette R. Comparison of the ability of 2 sunscreens to protect against polymorphous light eruption induced by a UV-A/UV-B metal halide lamp. Arch Dermatol 1999; 135: 1421-1422.
26. Azurdia RM, Pagliaro JA, Diffey BL, Rhodes LE. Sunscreen application by photosensitive patients is inadequate for protection. Br J Dermatol 1999; 140: 255-258.
27. Azurdia RM, Pagliaro JA, Rhodes LE. Sunscreen application technique in photosensitive patients: a quantitative assessment of the effect of education. Photodermatol Photoimmunol Photomed 2000; 16: 53-56.
28. Green C, Norris PG, Hawk JL. Photoallergic contact dermatitis from oxybenzone aggravating polymorphic light eruption. Contact Dermatitis 1991; 24: 62-63.
29. Ferguson J, Ibbotson S. The idiopathic photodermatoses. Semin Cutan Med Surg 1999; 18: 257-273.
30. Man I, Dawe RS, Ibbotson SH, Ferguson J. Is topical steroid effective in polymorphic light eruption. Br J Dermatol 2000; 142 (Suppl 57): 112-114.
31. Patel DC, Bellaney GJ, Seed PT, McGregor JM, Hawk JL. Efficacy of short-course oral prednisolone in polymorphic light eruption: a randomized controlled trial. Br J Dermatol 2000; 143: 828-831.
32. Van Praag MCG, Boom BW, Vermeer BJ. Diagnosis and treatment of polymorphous light eruption. Int J Dermatol 1994; 33: 233-239.
33. Krutmann J, Morita A. Mechanisms of ultraviolet (UV) B and UVA phototherapy. J Invest Dermatol Symp Proc 1999; 4: 70-72.
34. Gschnait F, Honigsmann H, Brenner W, Fritsch P, Wolff K. Induction of UV light tolerance by PUVA in patients with polymorphous light eruption. Br J Dermatol 1978; 99: 293-295.
35. Parrish JA, Le Vine MJ, Morison WL, Gonzalez E, Fitzpatrick TB. Comparison of PUVA and beta-carotene in the treatment of polymorphous light eruption. Br J Dermatol 1979; 100: 187-191.
36. Jansen CT, Karvonen J, Malmiharju T. PUVA therapy for polymorphous light eruptions: comparison of systemic methoxsalen and topical trioxsalen regimens and evaluation of local protective mechanisms. Acta Dermatol Venereol 1982; 62: 317-320.
37. Addo HA, Sharma SC. UVB phototherapy and photochemotherapy (PUVA) in the treatment of polymorphic light eruption and solar urticaria. Br J Dermatol 1987; 116: 539-547.
38. Morison WL, Momtaz K, Mosher DB, Parrish JA. UV-B phototherapy in the prophylaxis of polymorphous light eruption. Br J Dermatol 1982; 106: 231 233.
39. Murphy GM, Logan RA, Lovell CR, Morris RW, Hawk JL, Magnus IA. Prophylactic PUVA and UVB therapy in polymorphic light eruption - a controlled trial. Br J Dermatol 1987; 116: 531-538.
40. Bilsland D, George SA, Gibbs NK, Aitchison T, Johnson BE, Ferguson J. A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol 1993; 129: 708-712.
41. Man I, Dawe RS, Ferguson J. Artificial hardening for polymorphic light eruption: practical points from ten years' experience. Photodermatol Photoimmunol Photomed 1999; 15: 96-99.
42. Rucker BU, Haberle M, Koch HU, Bocionek P, Schriever KH, Hornstein OP. Ultraviolet light hardening in polymorphous light eruption - a controlled study comparing different emission spectra. Photodermatol Photoimmunol Photomed 1991; 8: 73-78.
43. Ortel B, Tanew A, Wolff K, Honigsmann H. Polymorphous light eruption: action spectrum and photoprotection. J Am Acad Dermatol 1986; 14: 748-753.
44. Molin L, Volden G. Treatment of polymorphous light eruption with PUVA and prednisolone. Photodermatology 1987; 4: 107-108.
45. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-124.
46. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and skin cancer PUVA. Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-1284.
47. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 1041-1045.
48. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761.
49. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-93.
50. Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol 1997; 108: 897-900.
51. Pasker-de Jong PC, Wielink G, van der Valk PG, van der Wilt GJ. Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Arch Dermatol 1999; 135: 834-840.
52. Slaper H, Schothorst AA, Van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatology 1986; 3: 271 283.
53. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994; 73: 2759-2764.
54. Wulf HC, Hansen AB, Bech-Thomsen N. Differences in narrow-band ultraviolet B and broad-spectrum ultraviolet photocarcinogenesis in lightly pigmented hairless mice. Photodermatol Photoimmunol Photomed 1994; 10: 192-197.
55. Gibbs NK, Traynor NJ, MacKie RM, Campbell I, Johnson BE, Ferguson J. Phototumorigenic potential of broad-band (280-340 nm) and narrow-band (310-313 nm) phototherapy sources cannot be predicted by their edematogenic potential in hairless mouse skin. J Invest Dermatol 1995; 104: 359-363.
56. Flindt-Hansen H, McFadden N, Eeg-Larsen T, Thune P. Effect of a new narrow-band UVB lamp on photocarcinogenesis in mice. Acta Dermatol Venereol 1991; 71: 245-248.
57. Young AR. Carcinogenicity of UVB phototherapy assessed. Lancet 1995; 345: 1431-1432.
58. Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol 1989; 125: 1377-1379.
59. Shipley DRV, Hewitt JB. Polymorphic light eruption treated with Cyclosporin. Br J Dermatol 2001; 144: 446-447.
60. Cowey FK, Whitehouse MW. Biochemical properties of anti-inflammatory drugs. VII. Inhibition of proteolytic enzymes in connective tissue by chloroquine (resochin) and related antimalarial antirheumatic drugs. Biochem Pharmacol 1966; 15: 1071-1084.
61. Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol 1987; 116: 379-386.
62. Corbett MF, Hawk JLM, Herxheimer A, et al. Controlled therapeutic trials in polymorphic light eruption. Br J Dermatol 1982; 107: 571-581.
63. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 1999; 140: 3-7.
64. The Royal College of Ophthalmologists. Ocular toxicity and hydroxychloroquine: guidelines for screening. London; 1998
65. Thune P. Chronic polymorphic light eruption. Particular wavebands and the effect of carotene therapy. Acta Dermatol Venereol 1976; 56: 127-133.
66. Wennersten G, Swanbeck G. Treatment of light sensitivity with carotenoids. Serum concentrations and light protection. Acta Dermatol Venereol 1974; 54: 491-499.
67. Jansen CT. Beta-carotene treatment of polymorphous light eruptions. Dermatologica 1974; 149: 363-373.
68. Mathews-Roth MM, Pathak MA, Fitzpatrick TB, Harber LH, Kass EH. Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 1977; 113: 1229-1232.
69. Nordlund JJ, Klaus SN, Mathews-Roth MM, Pathak MA. New therapy for polymorphous light eruption. Arch Dermatol 1973; 108: 710-712.
70. Jansen CT. Oral carotenoid treatment in polymorphous light eruption: a cross-over comparison with oxychloroquine and placebo. Photodermatology 1985; 2: 166-169.
71. Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol 1986; 115: 77-80.
72. Ortel B, Wechdorn D, Tanew A, Honigsmann H. Effect of nicotinamide on the phototest reaction in polymorphous light eruption. Br J Dermatol 1988; 118: 669-673.
73. Norris PG, Hawk JL. Polymorphic light eruption. Photodermatol Photoimmunol Photomed 1990; 7: 186-191.
74. Holzle E, Plewig G, von Kries R, Lehmann P. Polymorphous light eruption. J Invest Dermatol 1987; 88 (3 Suppl): 32s-38s.
75. Gonzalez E, Gonzalez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996; 35: 871-885.
76. Saul A, Flores O, Novales J. Polymorphous light eruption: treatment with thalidomide. Australas J Dermatol 1976; 17: 217-218.
77. Birt AR, Davis RA. Hereditary polymorphic light eruption of American Indians. Int J Dermatol 1975; 14: 105-111.
78. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering Thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-979.
79. 2 levels in skin and increases the threshold to provocation of polymorphic light eruption. J Invest Dermatol 1995; 105: 532-535.
80. Rhodes LE, Shahbakhti H, Azurdia RM, et al. Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers. Carcinogenesis 2003; 24: 919-925.
81. Rhodes LE, O'Farrell S, Jackson MJ, Friedmann PS. Dietary fish-oil supplementation in humans reduces ultraviolet B-induced erythemal responses but increases epidermal lipid peroxidation. J Invest Dermatol 1994; 103: 151-154.
82. 2 expression in UVB-irradiated human keratinocytes. J Invest Dermatol 2002; 118: 692-698.
83. Hadshiew I, Stab F, Untiedt S, Bohnsack K, Rippke F, Holzle E. Effects of topically applied antioxidants in experimentally provoked polymorphous light eruption. Dermatology 1997; 195: 362-368.
84. Rippke F, Wendt G, Bohnsack K, et al. Results of photoprovocation and field studies on the efficacy of a novel topically applied antioxidant in polymorphous light eruption. J Dermatol Treat 2001; 12: 3-8.
85. Eberlein-Konig B, Fesq H, Abeck D, Pryzbilla B, Placzek M, Ring J. Systemic vitamin C and vitamin E do not prevent photoprovocation test reactions in polymorphous light eruption. Photodermatol Photoimmunol Photomed 2000; 16: 50-52.
86. Przybilla B, Heppeler M, Ruzicka T. Preventive effect of an E. coli-filtrate (Colibiogen) in polymorphous light eruption. Br J Dermatol 1989; 121: 229-233.
87. Leonard F, Morel M, Kalis B, et al. Psoralen plus ultraviolet A in the prophylactic treatment of benign summer light eruption. Photodermatol Photoimmunol Photomed 1991; 8: 95-98.